These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33921332)

  • 21. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations.
    Truong DT; Ho K; Nhi HTY; Nguyen VH; Dang TT; Nguyen MT
    Sci Rep; 2024 May; 14(1):12218. PubMed ID: 38806555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
    Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
    J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Al-Anazi M; Al-Najjar BO; Khairuddean M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and
    Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.
    Abdelbaset MS; Abdel-Aziz M; Ramadan M; Abdelrahman MH; Abbas Bukhari SN; Ali TFS; Abuo-Rahma GEA
    Bioorg Med Chem; 2019 Mar; 27(6):1076-1086. PubMed ID: 30744932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study.
    Mansour NI; El-Sayed SM; El-Gohary NS; Abdel-Aziz NI; El-Subbagh HI; Ghaly MA
    Bioorg Chem; 2022 Oct; 127():105966. PubMed ID: 35728294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel cyclic NP1 reveals obstruction of EGFR kinase activity and attenuation of EGFR-driven cell lines.
    Jiwacharoenchai N; Tabtimmai L; Kiriwan D; Suwattanasophon C; Seetaha S; Sinthuvanich C; Choowongkomon K
    J Cell Biochem; 2022 Feb; 123(2):248-258. PubMed ID: 34633106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
    Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
    Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
    Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
    El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imidazo[1,2-a]quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies.
    Hasanvand Z; Oghabi Bakhshaiesh T; Peytam F; Firoozpour L; Hosseinzadeh E; Motahari R; Moghimi S; Nazeri E; Toolabi M; Momeni F; Bijanzadeh H; Khalaj A; Baratte B; Josselin B; Robert T; Bach S; Esmaeili R; Foroumadi A
    Bioorg Chem; 2023 Apr; 133():106383. PubMed ID: 36764231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.